Testing Sodium Thiosulfate to Protect Hearing During Medulloblastoma Treatment
Original title: A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a large late stage trial in people, but the answers are not in yet.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is testing whether an added drug can lower hearing loss from medulloblastoma treatment.
Who this trial is for. This trial is for people with newly diagnosed medulloblastoma, a cancer in the back of the brain, whose cancer is called low risk or average risk. For average-risk patients, it tests whether adding sodium thiosulfate to standard radiation and chemotherapy reduces hearing loss. For low-risk patients, it tests whether less radiation works as well as the stronger treatment and causes fewer side effects.
Where it stands. This trial has not reported results. It is measuring how much hearing loss happens with and without sodium thiosulfate. It is also checking that survival and the cancer coming back are not made worse. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: Standard treatment for this cancer usually works well, but one of the chemo drugs, cisplatin, can damage hearing. This trial is looking for ways to keep that from happening. Someone who might fit can ask their care team about it. The care team can explain whether it makes sense for their situation.
What it doesn't mean: This does not mean sodium thiosulfate is proven to protect hearing. A trial is a test, not a treatment that has been proven. Being in a trial is not a guarantee that a person will be helped. It is not a promise of a cure. Nothing here says less radiation is safe for anyone yet. Only the trial team can decide who is able to join.
Source: ClinicalTrials.gov, July 16, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.